Advances with analgesics and NSAIDs for the treatment of spinal disorders.

One of the major developments with regard to chronic non-malignant pain in these last few years has been a better understanding of the mechanisms that act to maintain pain, while inferences about the pathophysiology have facilitated therapeutic decision-making. This chapter reviews the strength of evidence for the therapeutic effect of pharmacological symptomatic approaches using non-steroidal anti-inflammatory agents, opioids and co-analgesics in acute and chronic back pain with an emphasis on the results of randomized controlled trials as well as on the need for long-term comparative trials of drug efficacy, toxicity and compliance.

[1]  A. Caelleigh,et al.  SOCIAL SCIENCES AND MEDICINE , 2001 .

[2]  K. Brandt,et al.  Educational Program for Physicians to Reduce Use of Non-Steroidal Anti-Inflammatory Drugs Among Community-Dwelling Elderly Persons: A Randomized Controlled Trial , 2001, Medical care.

[3]  C. Bombardier,et al.  A Critical Review of Reviews on the Treatment of Chronic Low Back Pain , 2001, Spine.

[4]  F. Breedveld,et al.  Efficacy of cyclooxygenase-2-specific inhibitors. , 2001, The American journal of medicine.

[5]  B. Gertz,et al.  Renal Effects of COX-2-Selective Inhibitors , 2001, American Journal of Nephrology.

[6]  Lise,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[7]  R. Deyo,et al.  Nonsteroidal Anti-Inflammatory Drugs for Low Back Pain: A Systematic Review Within the Framework of the Cochrane Collaboration Back Review Group , 2000, Spine.

[8]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[9]  H. Vuorela,et al.  Treatment of Acute Low Back Pain With the COX-2–Selective Anti-Inflammatory Drug Nimesulide: Results of a Randomized, Double-Blind Comparative Trial Versus Ibuprofen , 2000, Spine.

[10]  C. Woolf,et al.  Neuronal plasticity: increasing the gain in pain. , 2000, Science.

[11]  A. Whelton,et al.  Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. , 2000, American journal of therapeutics.

[12]  J. L. Dahl,et al.  Trends in medical use and abuse of opioid analgesics. , 2000, JAMA.

[13]  D. Henry,et al.  Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. , 2000, Archives of internal medicine.

[14]  T. Schnitzer,et al.  Efficacy of tramadol in treatment of chronic low back pain. , 2000, The Journal of rheumatology.

[15]  D. Fishbain.  Evidence-based data on pain relief with antidepressants , 2000, Annals of medicine.

[16]  F. Porreca,et al.  Spinal and Supraspinal Mechanisms of Neuropathic Pain , 2000, Annals of the New York Academy of Sciences.

[17]  A. Ansari.  The Efficacy of Newer Antidepressants in the Treatment of Chronic Pain: A Review of Current Literature , 2000 .

[18]  J. Glowinski,et al.  Use of morphine in nonmalignant joint pain: the Limoges recommendations. The French Society for Rheumatology. , 1999, Revue du rhumatisme.

[19]  C. Ng.  The image of madness: the public facing mental illness and psychiatric treatment , 1999 .

[20]  B. Bannwarth.  Risk-Benefit Assessment of Opioids in Chronic Noncancer Pain , 1999, Drug safety.

[21]  J. Guimón,et al.  Determining Factors and the Effects of Attitudes towards Psychotropic Medication , 1999 .

[22]  T. Schnitzer,et al.  Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study. , 1999, Arthritis and rheumatism.

[23]  C. Woolf,et al.  Neuropathic pain: aetiology, symptoms, mechanisms, and management , 1999, The Lancet.

[24]  J. Schofferman,et al.  Long-term opioid analgesic therapy for severe refractory lumbar spine pain. , 1999, The Clinical journal of pain.

[25]  M. Dougados,et al.  Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. , 1999, Rheumatology.

[26]  R. Moore,et al.  An Evidence-Based Resource for Pain Relief , 1998 .

[27]  R. Jamison,et al.  Opioid Therapy for Chronic Noncancer Back Pain: A Randomized Prospective Study , 1998, Spine.

[28]  D. Nutt.  Substance-P antagonists: a new treatment for depression? , 1998, The Lancet.

[29]  J. Vanneste,et al.  Prolonged treatment with transdermal fentanyl in neuropathic pain. , 1998, Journal of pain and symptom management.

[30]  T. Schnitzer,et al.  Non-NSAID pharmacologic treatment options for the management of chronic pain. , 1998, The American journal of medicine.

[31]  V. Desmet,et al.  Nimesulide-induced acute hepatitis: evidence from six cases. , 1998, Journal of hepatology.

[32]  T. Patterson,et al.  A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain , 1998, Pain.

[33]  P. Dayer,et al.  Use of the label "litigation neurosis" in patients with somatoform pain disorder. , 1998, General hospital psychiatry.

[34]  R. Blakely,et al.  Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.

[35]  S. Wessely,et al.  Medication misuse, abuse and dependence in chronic pain patients. , 1997, Journal of psychosomatic research.

[36]  O. Benkert,et al.  Public opinion on psychotropic drugs: an analysis of the factors influencing acceptance or rejection. , 1997, The Journal of nervous and mental disease.

[37]  E. MacGregor.  The doctor and the migraine patient , 1997, Neurology.

[38]  M. Bertolotti,et al.  Analgesic Drug Taking: Beliefs and Behavior Among Headache Patients , 1997, Headache.

[39]  E. Taal,et al.  Compliance in rheumatoid arthritis and the role of formal patient education. , 1997, Seminars in arthritis and rheumatism.

[40]  H. J. McQuay,et al.  A systematic review of antidepressants in neuropathic pain , 1996, Pain.

[41]  H. Wynne,et al.  Patient awareness of the adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs). , 1996, British journal of clinical pharmacology.

[42]  G. Guilbaud,et al.  Pathophysiology of joint pain. , 1996, Revue du rhumatisme.

[43]  A. Eschalier,et al.  Evidence of a central antinociceptive effect of paracetamol involving spinal 5HT3 receptors , 1995, Neuroreport.

[44]  J. Turner,et al.  Do antidepressant medications relieve chronic low back pain? , 1993, The Journal of family practice.

[45]  C. Akinsanya.  Cancer pain relief and palliative care , 1992 .

[46]  D. Blake,et al.  Patient non-compliance: deviance or reasoned decision-making? , 1992, Social science & medicine.

[47]  P. Dayer,et al.  Central analgesic effect of acetaminophen but not of aspirin , 1991, Clinical pharmacology and therapeutics.

[48]  K. Hole,et al.  Antinociceptive effect of paracetamol in rats is partly dependent on spinal serotonergic systems. , 1991, European journal of pharmacology.

[49]  K. Brøsen,et al.  The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms , 1990, Pain.

[50]  M. Connell,et al.  Estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2 levels in mouse brain. , 1990, European journal of pharmacology.

[51]  R. Dubner,et al.  Amitriptyline, but not lorazepam, relieves postherpetic neuralgia , 1988, Neurology.

[52]  I. Jurna,et al.  Central analgesic effect of paracetamol manifested by depression of nociceptive activity in thalamic neurones of the rat , 1987, Neuroscience Letters.

[53]  B. L. Fuller,et al.  Tissue selectivity and variability of effects of acetaminophen on arachidonic acid metabolism. , 1983, Prostaglandins, leukotrienes, and medicine.

[54]  Josef K. Wang.  Advances in Pain Research and Therapy , 1980 .

[55]  R. Brian Haynes,et al.  Compliance in Health Care , 1979 .

[56]  S. Ferreira,et al.  Central and peripheral antialgesic action of aspirin-like drugs. , 1978, European journal of pharmacology.

[57]  J. Vane,et al.  Inhibition of Prostaglandin Synthetase in Brain explains the Anti-pyretic Activity of Paracetamol (4-Acetamidophenol) , 1972, Nature.

[58]  M. Dougados,et al.  Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. , 2001, Arthritis and rheumatism.

[59]  D. Bhugra,et al.  The image of madness , 2000 .

[60]  M. Nordin,et al.  Patient-health care provider relationship in patients with non-specific low back pain: a review of some problem situations. , 1998, Bailliere's clinical rheumatology.

[61]  S. Linden,et al.  COMPLIANCE MONITORING OF NSAID DRUG THERAPY IN ANKYLOSING SPONDYLITIS, EXPERIENCES WITH AN ELECTRONIC MONITORING DEVICE , 1996 .

[62]  Burkhart Bromm,et al.  Pain and the brain : from nociception to cognition , 1995 .